Education
About Us
Working with TipRanks
Follow Us
Third Harmonic Bio, Inc. (THRD)
:THRD
THRD Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Third Harmonic Bio, Inc. News
THRD FAQ
What was Third Harmonic Bio, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Third Harmonic Bio, Inc.’s market cap?
Currently, no data Available
When is Third Harmonic Bio, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Third Harmonic Bio, Inc.’s earnings last quarter?
Currently, no data Available
Is Third Harmonic Bio, Inc. overvalued?
According to Wall Street analysts Third Harmonic Bio, Inc.’s price is currently Undervalued.
Does Third Harmonic Bio, Inc. pay dividends?
Third Harmonic Bio, Inc. does not currently pay dividends.
What is Third Harmonic Bio, Inc.’s EPS estimate?
Third Harmonic Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Third Harmonic Bio, Inc. have?
Currently, no data Available
What happened to Third Harmonic Bio, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Third Harmonic Bio, Inc.?
Currently, no hedge funds are holding shares in THRD
Company Description
Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc. (THRD) is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of allergic and inflammatory diseases. Leveraging its expertise in immunology and drug development, the company aims to address unmet medical needs by creating targeted therapies that modulate specific pathways involved in allergic and inflammatory responses.
Ownership Overview
―
Insiders
1.53%
Mutual Funds
― Other Institutional Investors
97.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---